AbbVie, Washington state strike subscription payment deal for hepatitis C treatments

The Washington State Health Care Authority has selected AbbVie to supply hepatitis C medication under a subscription-based payment model, the agency announced April 26.

Under the terms of the contract, the state will pay a fixed dollar amount to AbbVie for an unlimited supply of hepatitis C drugs.

The contract is part of the state's plan to eliminate hepatitis C by 2030.

Last month, the state of Louisiana struck a deal with a Gilead Sciences subsidiary to supply hepatitis C medication under a subscription-style payment model.

Both Washington and Louisiana plan to start their programs this summer.

More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody's says

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months